Both in Pharmaceuticals
Janux Therapeutics vs Harrow
Over the past year JANX returned −32.7% and HROW returned −18.6%; their daily moves had a correlation of 0.09.
JANX −32.7% HROW −18.6%Growth of $1, one year, split-adjusted
| Metric | JANX | HROW |
|---|---|---|
| Price | $18.18 | $28.75 |
| Market cap | $1.11B | $1.08B |
| Today | +2.02% | +0.74% |
| 1 month | +8.3% | −5.3% |
| 6 months | +24.4% | −28.6% |
| Year to date | +31.7% | −41.3% |
| 1 year | −33.6% | −20.1% |
| Revenue growth (YoY) | — | +10.9% |
| Gross margin | 100.0% | 71.3% |
| Net margin | −214.0% | −24.4% |
| P/E (TTM) | — | — |
| Price / sales | 46.3× | 3.9× |
| Net cash | $970.9M | -$208.5M |
| Dividend yield | — | — |
| Volatility (60d) | 47.8% | 39.9% |
| Short % of float | 11.8% | 24.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).